Patient-derived synovial organoids as an inflammatory driver of cartilage degeneration in in-vitro engineered human joint disease models (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2023; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "For the PoC, activated organoids were treated with baricitinib, a selective JAK/STAT pathway inhibitor... These findings establish stromal-immune PDOs as biologically active 3D inflammatory niches capable of transmitting joint pathology to the cartilage tissue and responding to clinically relevant therapeutics. This scalable platform offers a robust toolset for studying disease mechanisms and screening therapeutics in arthritic conditions."
Preclinical • Inflammatory Arthritis • Orthopedics • Osteoarthritis • Rheumatology • CXCL8 • IL6 • MMP13 • PACERR • PTGS2 • TNFA
|
|
André N. Tiaden1; Simone Haener-Massimi1; Atharva Damle1; Yasmina Bauer1; Ulrich A. Walker2; Petros Ismailidis3; Florian B. Imhoff3; Diego Kyburz3; Andrea Barbero1; Stavros Giaglis1
|